Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry
Chi Chiu Mok, Ho So, Cheuk Wan Yim, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 2, pp. 358-365
Closed Access | Times Cited: 19

Showing 19 citing articles:

JAK inhibitor selectivity: new opportunities, better drugs?
Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 10, pp. 649-665
Closed Access | Times Cited: 18
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access | Times Cited: 1
The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations
Jérôme Avouac, Hafid Aït-Oufella, Caroline Habauzit, et al.
Rheumatology and Therapy (2025)
Open Access | Times Cited: 1
Stroke risk in rheumatoid arthritis patients: exploring connections and implications for patient care
Ola A. Al-Ewaidat, Moawiah M. Naffaa
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 5
Updates on interstitial lung disease and other selected extra-articular manifestations of rheumatoid arthritis
Elena Myasoedova, Eric L. Matteson
Current Opinion in Rheumatology (2024) Vol. 36, Iss. 3, pp. 203-208
Closed Access | Times Cited: 4
Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis
Styliani Partalidou, Dimitrios Patoulias, Kleopatra Deuteraiou, et al.
Mediterranean Journal of Rheumatology (2024) Vol. 35, Iss. Suppl 1, pp. 10-10
Open Access | Times Cited: 4
Patient-Centric Approach for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease in Older People
Kevin T Mueller, Alene A Saavedra, Lauren A. O’Keeffe, et al.
Drugs & Aging (2025)
Closed Access
Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort study
Yongtai Cho, Dongwon Yoon, Farzin Khosrow‐Khavar, et al.
Journal of Internal Medicine (2025)
Open Access
Prevention of herpes zoster in acquired immunocompromised conditions: Review of updates and perspectives from Hong Kong
Desmond Y. H. Yap, Gordon Chun‐Kau Chan, So Ho, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access
Frailty and cardiovascular safety of JAK inhibitors versus TNF inhibitors in rheumatoid arthritis: a real-world comparative study of drug effects and patient profiles
Ettore Silvagni, Alessandra Bortoluzzi, Giuseppe Occhino, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Advances in Axial Spondyloarthritis Treatment: The Role of Janus Kinase Inhibitors
Fatrian Dwicahya, Cahyo Wibisono Nugroho, Naufalluthfi Widodo
Indian Journal of Rheumatology (2025)
Open Access
Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study
Po‐Ku Chen, Shih‐Hsin Chang, Yi‐Ming Chen, et al.
Clinical Rheumatology (2024) Vol. 43, Iss. 8, pp. 2503-2511
Closed Access | Times Cited: 3
Impact of age and cardiovascular risk factors on the incidence of adverse events in patients with rheumatoid arthritis treated with Janus Kinase inhibitors: data from a real-life multicentric cohort
Stefano Gentileschi, Carla Gaggiano, Arianna Damiani, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population
Călin D. Popa, M. Opdam, Nathan den Broeder, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 8, pp. 2142-2146
Closed Access | Times Cited: 4
The use of JAK inhibitors and the impact of comorbidities
Fabiola Atzeni, Alessandra Alciati
Lara D. Veeken (2023) Vol. 63, Iss. 2, pp. 273-274
Open Access | Times Cited: 1
Selective JAK-Inhibitors in Spondyloarthritis
Konstantinos D Vassilakis, Konstantina Magiouf, Stefan Siebert, et al.
Mediterranean Journal of Rheumatology (2024) Vol. 35, Iss. Suppl 1, pp. 27-27
Open Access
L’évolution des prescriptions en rhumatologie: un regard à travers la pharmaco-épidémiologie
Yves‐Marie Pers
Revue du Rhumatisme (2024) Vol. 91, Iss. 5, pp. 635-641
Open Access
Prevalence and Factors Associated with De-escalation of Anti-TNFs in Older Adults with Rheumatoid Arthritis: A Medicare Claims-Based Observational Study
Jiha Lee, Navasuja Kumar, Mohammed Kabeto, et al.
Drugs & Aging (2024) Vol. 41, Iss. 7, pp. 601-613
Closed Access
Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors
Elisabet Castañeda-Estévez, C Vergara-Dangond, Martina Steiner, et al.
Pharmaceuticals (2024) Vol. 18, Iss. 1, pp. 22-22
Open Access
Page 1

Scroll to top